• LaiGillianne Geet YiGGYDivision of Medical Oncology, National Cancer Centre Singapore., Xin Min Cheng, Yvonne Li'en Ang, Kevin Lee Min Chua, Jens Samol, Ross Soo, Daniel Shao Weng Tan, LimTony Kiat HonTKHDivision of Pathology, Singapore General Hospital, Singapore., and Darren Wan Teck Lim.
• Division of Medical Oncology, National Cancer Centre Singapore.
• Ann Acad Med Singap. 2023 Jul 28; 52 (7): 364373364-373.

IntroductionLung cancer remains an important cause of cancer-related mortality in Singapore, with a greater proportion of non-smokers diagnosed with non-small cell lung cancer (NSCLC) in the past 2 decades. The higher prevalence of targetable genomic alterations in lung cancer diagnosed in Singapore compared with countries in the West, as well as the expanding therapeutic landscape for NSCLC in the era of precision medicine, are both factors that underscore the importance of efficient and effective molecular profiling.MethodThis article provides consensus recommendations for biomarker testing for early-stage to advanced NSCLC. These recommendations are made from a multidisciplinary group of lung cancer experts in Singapore with the aim of improving patient care and long-term outcomes.ResultsThe recommendations address the considerations in both the advanced and early-stage settings, and take into account challenges in the implementation of biomarker testing as well as the limitations of available data. Biomarker testing for both tumour tissue and liquid biopsy are discussed.ConclusionThis consensus statement discusses the approaches and challenges of integrating molecular testing into clinical practice for patients with early- to late-stage NSCLC, and provides practical recommendations for biomarker testing for NSCLC patients in Singapore.

22 keywords...

hide…